---
title: "BioSig Technologies Rebrands to Streamex Corp."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256987183.md"
description: "BioSig Technologies has announced its rebranding to Streamex Corp., effective September 12, 2025, following a merger with Streamex Exchange Corporation. The new Nasdaq ticker symbol will be ‘STEX’. This rebranding aims to enhance its business model by integrating tokenization technology in the commodities market. Despite the rebranding, shareholder rights remain unchanged. Analyst ratings for BSGM stock show a Buy with a $10.00 price target, but concerns about financial difficulties and valuation challenges persist, with Spark rating it as Underperform."
datetime: "2025-09-11T20:35:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256987183.md)
  - [en](https://longbridge.com/en/news/256987183.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256987183.md)
generator: "portal-rs"
---

# BioSig Technologies Rebrands to Streamex Corp.

BioSig Technologies ( (BSGM) ) has shared an update.

On September 10, 2025, BioSig Technologies announced its rebranding to Streamex Corp., effective September 12, 2025, with a new Nasdaq ticker symbol ‘STEX’. This strategic move follows a merger with Streamex Exchange Corporation, aiming to expand its business model and growth strategy. The rebranding does not affect shareholder rights or the company’s CUSIP number, and existing stock certificates remain valid. The change reflects a shift towards integrating tokenization technology in the commodities market, enhancing the company’s industry positioning.

The most recent analyst rating on (BSGM) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on BioSig Technologies stock, see the BSGM Stock Forecast page.

**Spark’s Take on BSGM Stock**

According to Spark, TipRanks’ AI Analyst, BSGM is a Underperform.

BioSig Technologies faces significant financial difficulties, with persistent losses, high leverage, and negative cash flow trends. While technical analysis indicates some short-term momentum, potential overbought conditions warrant caution. The negative P/E ratio further underscores valuation challenges and risks associated with the stock.

To see Spark’s full report on BSGM stock, click here. 

**More about BioSig Technologies**

BioSig Technologies, Inc. is a medical device technology company specializing in advanced digital signal processing technology for cardiovascular arrhythmias treatment. Streamex Exchange Corporation, a subsidiary, focuses on Real World Asset tokenization, particularly in the gold and commodities market.

**Average Trading Volume:** 1,078,518

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $157M

### Related Stocks

- [BSGM.US](https://longbridge.com/en/quote/BSGM.US.md)
- [STEX.US](https://longbridge.com/en/quote/STEX.US.md)

## Related News & Research

- [STEX: First revenue from tokenized gold, $41.8M liquidity, and new product launches drive growth](https://longbridge.com/en/news/295977814.md)
- [Streamex adds Inspira Financial as custodian for GLDY Class B shares](https://longbridge.com/en/news/293334676.md)
- [Streamex teams with Wintermute to provide 24/7 instant liquidity for GLDY token](https://longbridge.com/en/news/293603089.md)
- [Streamex launches share buyback of up to 10 million shares at up to $2 each](https://longbridge.com/en/news/291925209.md)
- [Biosig Technologies (NASDAQ:STEX) CIO Mitchell Young Williams Sells 263,863 Shares](https://longbridge.com/en/news/285132932.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**